Cellectis (CLLS) Cash from Operations Growth (3y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 37.40% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 16.64% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -7.60% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 34.32% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | 18.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.37% |
| Dec 31, 2025 | -104.02% |
| Sep 30, 2025 | 60.78% |
| Jun 30, 2025 | 24.09% |
| Mar 31, 2025 | 22.32% |
| Dec 31, 2024 | 86.94% |
| Sep 30, 2024 | 42.35% |
| Jun 30, 2024 | 84.73% |
| Mar 31, 2024 | 17.10% |
| Dec 31, 2023 | 48.57% |
| Sep 30, 2023 | 12.60% |
| Jun 30, 2023 | 5.02% |
| Mar 31, 2023 | -177.75% |
| Dec 31, 2022 | 44.95% |
| Sep 30, 2022 | -4.77% |
| Jun 30, 2022 | -3.57% |
| Mar 31, 2022 | -17.80% |
| Dec 31, 2021 | -0.77% |
| Sep 30, 2021 | -26.55% |
| Jun 30, 2021 | 1.13% |
| Mar 31, 2021 | -27.00% |
| Dec 31, 2020 | -52.72% |
| Sep 30, 2020 | -18.24% |
| Jun 30, 2020 | -8.51% |
| Mar 31, 2020 | 27.85% |
| Dec 31, 2019 | -85.61% |
| Sep 30, 2019 | -128.17% |
| Jun 30, 2019 | -25.47% |
| Mar 31, 2019 | -1.20% |
| Dec 31, 2018 | -40.02% |
| Sep 30, 2018 | -43.19% |
| Jun 30, 2018 | 11.12% |
| Mar 31, 2018 | -143.89% |